Palacios E, Piñon-López M J, Racotta I S, Racotta R
Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional (ICN), México Distrito Federal, Mexico.
Metabolism. 1995 Dec;44(12):1631-8. doi: 10.1016/0026-0495(95)90086-1.
Intraperitoneal (IP) fat accumulation in humans is a risk factor for a number of diseases. We tried to increase this particular adipose mass in rats by long-term administration of low-dose dexamethasone (Dex) and/or elimination of other fat depots. Male adult Wistar rats were lipectomized (Lip) or sham-operated (Sh). Bilateral lipectomy of retroperitoneal and inguinal fat pads was performed under anesthesia with Na pentobarbital 40 mg/kg supplemented with ether. After 8 days, half the animals of each group received Dex in their drinking water (0.1 microgram/mL) while the other half received water (W), for a total of four groups: Sh-W, Lip-W, Sh-Dex, and Lip-Dex. Body weight (BW) and food and water intake were measured throughout the treatment period. A glucose tolerance test was performed 34 days after starting Dex treatment, and then rats were killed, fat depots were weighed, and plasma and liver were obtained for metabolic determinations. Dex rats ate the same amount of food as W controls, but gained significantly less weight (2.02 +/- 0.18 v 3.82 +/- 0.10 g/d, P < .01). Mean daily W intake was approximately 40 mL/d in all groups, which means that Dex rats ingested approximately 4 micrograms/d Dex. Average glycemic values during the 180-minute glucose tolerance test were as follows: Sh-W, 162 +/- 13; Lip-W, 166 +/- 7; Sh-Dex, 118 +/- 6; and Lip-Dex, 229 +/- 27 mg/dL. These values show that glucose tolerance was improved by Dex treatment alone, but was impaired in Lip-Dex animals. The same trend was evident for the relative weights (percent of BW) of two intact adipose depots: IP and epididymal (EPI) (Sh-W, 2.08 +/- 0.13 and 1.35 +/- 0.11, respectively; Lip-W, 1.67 +/- 0.15 and 1.17 +/- 0.11; Sh-Dex, 1.66 +/- 0.10 and 1.28 +/- 0.07; Lip-Dex, 2.41 +/- 0.11 and 1.53 +/- 0.09). Average glycemia for all rats was significantly correlated with IP (r = .55, P < .01) but not with EPI; moreover it was correlated in the Sh-W control group (r = .81, P < .05), suggesting a normal relation between these variables. Liver triglycerides (LTG), which were elevated in Dex rats, were also correlated with IP (r = .51, P < .02 for all rats and r = .82, P < .05 for Sh-W rats). The results show that long-term administration of low-dose Dex has some different effects in normal versus Lip rats concerning mainly the IP fat depot, the relative mass of which seems to significantly affect glucose tolerance.
人类腹腔内(IP)脂肪堆积是多种疾病的危险因素。我们试图通过长期给予低剂量地塞米松(Dex)和/或去除其他脂肪库来增加大鼠的这种特定脂肪量。成年雄性Wistar大鼠接受了脂肪切除术(Lip)或假手术(Sh)。在40mg/kg戊巴比妥钠并补充乙醚麻醉下,进行双侧腹膜后和腹股沟脂肪垫切除术。8天后,每组一半动物在饮用水中给予Dex(0.1μg/mL),另一半给予水(W),共四组:Sh-W、Lip-W、Sh-Dex和Lip-Dex。在整个治疗期间测量体重(BW)、食物和水摄入量。在开始Dex治疗34天后进行葡萄糖耐量试验,然后处死大鼠,称量脂肪库重量,并获取血浆和肝脏进行代谢测定。Dex组大鼠与W对照组摄入相同量的食物,但体重增加明显较少(2.02±0.18对3.82±0.10g/d,P<.01)。所有组的平均每日水摄入量约为40mL/d,这意味着Dex组大鼠每天摄入约4μg Dex。180分钟葡萄糖耐量试验期间的平均血糖值如下:Sh-W组为162±13;Lip-W组为166±7;Sh-Dex组为118±6;Lip-Dex组为229±27mg/dL。这些值表明,单独使用Dex治疗可改善葡萄糖耐量,但在Lip-Dex组动物中受损。两个完整脂肪库的相对重量(占BW的百分比)也有相同趋势:IP和附睾(EPI)(Sh-W组分别为2.08±0.13和1.35±0.11;Lip-W组为1.67±0.15和1.17±0.11;Sh-Dex组为1.66±0.10和1.28±0.07;Lip-Dex组为2.41±0.11和1.53±0.09)。所有大鼠的平均血糖与IP显著相关(r=.55,P<.01),但与EPI无关;此外,在Sh-W对照组中相关(r=.81,P<.05),表明这些变量之间存在正常关系。Dex组大鼠肝脏甘油三酯(LTG)升高,也与IP相关(所有大鼠r=.51,P<.02;Sh-W组大鼠r=.82,P<.05)。结果表明,长期给予低剂量Dex对正常大鼠和Lip大鼠有一些不同的影响,主要涉及IP脂肪库,其相对质量似乎显著影响葡萄糖耐量。